Search Results - "GRAM, L. F"

Refine Results
  1. 1

    Venlafaxine versus imipramine in painful polyneuropathy: A randomized, controlled trial by SINDRUP, S. H, BACH, F. W, MADSEN, C, GRAM, L. F, JENSEN, T. S

    Published in Neurology (22-04-2003)
    “…Tricyclic antidepressants (TCA) are often used in the treatment of painful polyneuropathy. Venlafaxine is a serotonin and weak noradrenaline reuptake inhibitor…”
    Get full text
    Journal Article
  2. 2

    CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants:a first step towards subpopulation-specific dosages by Kirchheiner, J., Brøsen, K., Dahl, M. L., Gram, L. F., Kasper, S., Roots, I., Sjöqvist, F., Spina, E., Brockmöller, J.

    Published in Acta psychiatrica Scandinavica (01-09-2001)
    “…Objective: This review aimed to provide distinct dose recommendations for antidepressants based on the genotypes of cytochrome P450 enzymes CYP2D6 and CYP2C19…”
    Get full text
    Journal Article
  3. 3

    Contacts to the health care system prior to suicide: a comprehensive analysis using registers for general and psychiatric hospital admissions, contacts to general practitioners and practising specialists and drug prescriptions by Andersen, U. A., Andersen, M., Rosholm, J. U., Gram, L. F.

    Published in Acta psychiatrica Scandinavica (01-08-2000)
    “…Objective: The purpose of this study was to describe suicides' contacts with various parts of the health‐care system. Method: Data on 472 people who committed…”
    Get full text
    Journal Article
  4. 4

    The predictive validity of atypical neurovegetative depressive symptoms identified by the first principal component in the DUAG trial of moclobemide versus clomipramine by Bech, P, Stage, K.B, Larsen, J.K, Vestergaard, P, Gram, L.F

    Published in Journal of affective disorders (01-11-2012)
    “…Abstract Objective To investigate to what extent the primary depression subtype atypical depression can predict differential outcome of the mono-amino-oxidase…”
    Get full text
    Journal Article
  5. 5

    Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine by JEPPESEN, U, GRAM, L. F, VISTISEN, K, LOFT, S, POULSEN, H. E, BRØSEN, K

    “…The purpose of this pharmacokinetic study was to investigate the dose-dependent inhibition of model substrates for CYP2D6, CYP2C19 and CYP1A2 by four marketed…”
    Get full text
    Journal Article
  6. 6

    Codeine and morphine in extensive and poor metabolizers of sparteine : pharmacokinetics, analgesic effect and side effects by POULSEN, L, BRØSEN, K, ARENDT-NIELSEN, L, GRAM, L. F, ELBAEK, K, SINDRUP, S. H

    “…Codeine O-demethylation to morphine is catalysed by the genetic polymorphic sparteine oxygenase (CYP2D6). The objective of the present study was to assess the…”
    Get full text
    Journal Article
  7. 7

    Socio-economic inequalities in first-time use of antidepressants: a population-based study by HANSEN, D. G, SØNDERGAARD, J, VACH, W, GRAM, L. F, ROSHOLM, J. U, MORTENSEN, P. B, KRAGSTRUP, J

    Published in European journal of clinical pharmacology (01-03-2004)
    “…To analyse whether first-time use of antidepressants (incidence) and selection of TCAs (tricyclic antidepressants) versus new-generation drugs are associated…”
    Get full text
    Journal Article
  8. 8

    Clinical significance of the sparteine/debrisoquine oxidation polymorphism by BRØSEN, K, GRAM, L. F

    Published in European journal of clinical pharmacology (01-01-1989)
    “…The sparteine/debrisoquine oxidation polymorphism results from differences in the activity of one isozyme of cytochrome P450, the P450db1 (P450 IID1). The…”
    Get full text
    Journal Article
  9. 9

    Psychopharmacological treatment and psychiatric morbidity in 390 cases of suicide with special focus on affective disorders by Andersen, U. A., Andersen, M., Rosholm, J. U., Gram, L. F.

    Published in Acta psychiatrica Scandinavica (01-12-2001)
    “…Objective: The aim of this study was, on the basis of data from health‐care registers, to describe the adequacy of psychopharmacological treatment in suicides…”
    Get full text
    Journal Article
  10. 10

    The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy by Sindrup, S H, Bjerre, U, Dejgaard, A, Brøsen, K, Aaes-Jørgensen, T, Gram, L F

    Published in Clinical pharmacology and therapeutics (01-11-1992)
    “…The effect of the selective serotonin reuptake inhibitor citalopram on diabetic neuropathy symptoms was examined in a double-blind, placebo-controlled,…”
    Get more information
    Journal Article
  11. 11

    Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention by Hallas, J, Harvald, B, Gram, L F, Grodum, E, Brøsen, K, Haghfelt, T, Damsbo, N

    Published in Journal of internal medicine (01-08-1990)
    “…Three hundred and thirty-three consecutive patients in a medical ward were evaluated in a high-intensity monitoring scheme for drug events as a cause of…”
    Get more information
    Journal Article
  12. 12

    Inhibition by paroxetine of desipramine metabolism in extensive but not poor metabolizers of sparteine by BRØSEN, K, HANSEN, J. G, NIELSEN, K. K, SINDRUP, S. H, GRAM, L. F

    Published in European journal of clinical pharmacology (01-05-1993)
    “…Nine extensive metabolizers (EMs) and eight poor metabolizers (PMs) of sparteine took a single oral dose of 100 mg of desipramine HCI before and while taking…”
    Get full text
    Journal Article
  13. 13

    Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms by Sindrup, S H, Brøsen, K, Hansen, M G, Aaes-Jørgensen, T, Overø, K F, Gram, L F

    Published in Therapeutic drug monitoring (01-02-1993)
    “…The relationship between the metabolism of the selective serotonin reuptake inhibitor citalopram and the sparteine and mephenytoin oxidation polymorphisms was…”
    Get more information
    Journal Article
  14. 14

    Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study by Gram, L F, Guentert, T W, Grange, S, Vistisen, K, Brøsen, K

    Published in Clinical pharmacology and therapeutics (01-06-1995)
    “…The reversible monoamine oxidase A inhibitor moclobemide was given in single (300 mg) and multiple doses (600 mg/day) to 11 male and four female healthy…”
    Get more information
    Journal Article
  15. 15

    Changes in the pattern of antidepressant use upon the introduction of the new antidepressants: a prescription database study by ROSHOLM, J.-U, GRAM, L. F, ISACSSON, G, HALLAS, J, BERGMAN, U

    “…To study whether the newer antidepressants have changed the patterns of antidepressant use, and whether the claimed better adverse effect profile of the lower…”
    Get full text
    Journal Article
  16. 16

    Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine by Sindrup, S H, Brøsen, K, Bjerring, P, Arendt-Nielsen, L, Larsen, U, Angelo, H R, Gram, L F

    Published in Clinical pharmacology and therapeutics (01-12-1990)
    “…The analgesic efficacy and kinetics of a single oral dose of 75 mg codeine was investigated in 12 extensive metabolizers and 12 poor metabolizers of sparteine…”
    Get more information
    Journal Article
  17. 17

    The analgesic effect of codeine as compared to imipramine in different human experimental pain models by Enggaard, Thomas P, Poulsen, Lars, Arendt-Nielsen, Lars, Hansen, Steen Honoré, Bjørnsdottir, Inga, Gram, Lars F, Sindrup, Søren H

    Published in Pain (Amsterdam) (01-05-2001)
    “…The hypoalgesic effect of single oral doses of 100 mg imipramine and 125 mg codeine was evaluated in a randomised, placebo-controlled, double-blind, 3-way…”
    Get full text
    Journal Article
  18. 18

    Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double‐blind cross‐over study by Sindrup, SH, Gram, LF, Skjold, T, Grodum, E, Brosen, K, Beck‐Nielsen, H

    Published in British journal of clinical pharmacology (01-11-1990)
    “…1. The effect of clomipramine and desipramine on diabetic neuropathy symptoms was examined in a double‐blind, randomised, placebo controlled, cross‐over study…”
    Get full text
    Journal Article
  19. 19

    Is overuse of sumatriptan a problem ? A population-based study by GAIST, D, HALLAS, J, SINDRUP, S. H, GRAM, L. F

    “…Sumatriptan is highly efficacious in aborting acute attacks of migraine. Owing to recent reports of misuse of sumatriptan, we performed a study of its use in a…”
    Get full text
    Journal Article
  20. 20

    Inappropriate use of sumatriptan: population based register and interview study by Gaist, David, Tsiropoulos, Ioannis, Sindrup, Søren H, Hallas, Jesper, Rasmussen, Birthe K, Kragstrup, Jakob, Gram, Lars F

    Published in BMJ (02-05-1998)
    “…Sumatriptan ranked second in expenditure on drugs for outpatients in Denmark in 1995, and the 5% of patients who were heavy users accounted for nearly 40% of…”
    Get full text
    Journal Article